Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06969755 · ClinicalTrials.gov registry record · Phase 4
Biomarkers to Enhance Early Schizophrenia Treatment
A Phase 4 study, sponsored by Northwell Health.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 180
- Enrollment target
NCT06969755 is a Phase 4 study that is actively recruiting participants, run by Northwell Health. The registered enrollment target is 180 participants.
The verdict
NCT06969755, a Phase 4 study, is actively recruiting participants, sponsored by Northwell Health.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 180 participants
- Enrollment target
Study Summary
This study is recruiting participants who are experiencing a first episode of psychosis and who have certain genetic factors that may make them respond better to certain medications that are used to treat people with psychosis.
Interventions
- DRUG clozapine
- DRUG risperidone
- DRUG aripiprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2025-09-30 |
| Est. Completion | 2030-07-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06969755
The ClinicalTrials.gov registry entry for NCT06969755 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwell Health, which has 370 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which clozapine is the first listed.
NCT06969755 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06969755 about?
NCT06969755 is a clinical study titled "Biomarkers to Enhance Early Schizophrenia Treatment". This study is recruiting participants who are experiencing a first episode of psychosis and who have certain genetic factors that may make them respond better to certain medications that are used to treat people with psychosis.
What is the current status of trial NCT06969755?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 180 participants. The study started on 2025-09-30. Estimated completion is 2030-07-30.
What interventions are being tested in trial NCT06969755?
The interventions under investigation include: clozapine (DRUG), risperidone (DRUG), aripiprazole (DRUG).
Who is sponsoring clinical trial NCT06969755?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.